A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

PURPOSE: Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Steidl, Eike, Filipski, Katharina, Zeiner, Pia S., Wagner, Marlies, Fokas, Emmanouil, Forster, Marie-Therese, Ronellenfitsch, Michael W., Divé, Iris, Steinbach, Joachim P., Harter, Patrick N., Bähr, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236451/
https://www.ncbi.nlm.nih.gov/pubmed/33538917
http://dx.doi.org/10.1007/s00432-021-03511-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236451/
https://www.ncbi.nlm.nih.gov/pubmed/33538917
http://dx.doi.org/10.1007/s00432-021-03511-y

Ejemplares similares